Abstract
Cancer targeting with peptides has become promising with the emergence of combinatorial peptide techniques such as phage display. Using phage display under stringent screening conditions, we selected five distinct peptides that specifically recognized the CD21 receptor, a cell surface marker of malignant B cell lymphoma. Two highly hydrophobic sequences were excluded (RLAYWCFSGLFLLVC and PVAAVSFVPYLVKTY). The binding affinity toward CD21 of the other three selected peptides (RMWPSSTVNLSAGRR, PNLDFSPTCSFRFGC, and GRVPSMFGGHFFFSR) was analyzed with fluorescence quenching. Their dissociation constants were determined to be within the micromolar range. On the basis of the results of phage ELISA, competitive phage ELISA, and fluorescence quenching, the binding sites of the three selected peptides were found to reside within the first four short consensus repeats of CD21 (SCR1-4). The peptide RMWPSSTVNLSAGRR (P1) was bound to the N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer, a potential drug carrier for chemotherapeutic agents, and the surface binding properties of HPMA copolymer-P1 conjugates were investigated. Specific interactions were observed between HPMA copolymer-P1 conjugates and surface-bound receptor. Binding of HPMA ...Continue Reading
References
Feb 10, 1989·Cell·G R NemerowN R Cooper
Jun 1, 1993·European Journal of Immunology·T A McNearneyM P Dierich
Jan 1, 1996·Journal of Drug Targeting·V OmelyanenkoJ Kopecek
Feb 26, 1998·Immunopharmacology·W M ProdingerM P Dierich
May 20, 1999·Journal of Controlled Release : Official Journal of the Controlled Release Society·T MinkoJ Kopecek
Jul 17, 1999·Immunopharmacology·V Frémeaux-BacchiE M Fischer
Jun 7, 2000·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·J KopecekZ Lu
Aug 8, 2001·Journal of Controlled Release : Official Journal of the Controlled Release Society·S WróblewskiJ Kopecek
Nov 8, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·J M GuthridgeV M Holers
Apr 1, 1997·Chemical Reviews·George P. Smith, Valery A. Petrenko
Jul 5, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Leslie J MatthewsGeorge P Smith
Oct 3, 2003·Journal of Cellular Biochemistry·Linda A Landon, Susan L Deutscher
Jan 30, 2004·Expert Review of Anticancer Therapy·Jonathan W Friedberg, Richard I Fisher
Mar 23, 2005·Critical Reviews in Oncology/hematology·M Stern, R Herrmann
Apr 26, 2005·Journal of Drug Targeting·Girja S Shukla, David N Krag
Citations
Jan 22, 2009·Bioconjugate Chemistry·Russell N JohnsonJindrich Kopecek
Dec 9, 2009·Bioconjugate Chemistry·Rob S Burke, Suzie H Pun
Nov 14, 2006·Biomacromolecules·Hui DingJindrich Kopecek
Feb 23, 2010·Chemical Reviews·Susan L Deutscher
Nov 3, 2012·Therapeutic Delivery·Chuda Chittasupho
Aug 3, 2007·Journal of Drug Targeting·Hui DingJindrich Kopecek
Apr 1, 2007·Expert Opinion on Drug Discovery·Lauren Rh Krumpe, Toshiyuki Mori
Apr 22, 2014·Journal of Controlled Release : Official Journal of the Controlled Release Society·Jiyuan Yang, Jindřich Kopeček
Jan 12, 2007·Journal of Controlled Release : Official Journal of the Controlled Release Society·Twan LammersGert Storm
Jan 6, 2010·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Rudolph L JulianoHyun Min Kang
May 24, 2016·Advanced Drug Delivery Reviews·Ruiwu LiuKit S Lam
Jul 21, 2015·Biomaterials Science·Te-Wei Chu, Jindřich Kopeček
May 15, 2018·Oncotarget·Yu-Hsiu SuChin-Kai Chuang
Mar 10, 2020·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Hong XuChuanbin Mao
Jan 27, 2010·Angewandte Chemie·Kuangshi WuJindrich Kopecek
Aug 1, 2020·Advanced Drug Delivery Reviews·Jindřich Kopeček, Jiyuan Yang
Sep 10, 2008·Bioconjugate Chemistry·Ivo R RuttekolkRoland Brock
Sep 21, 2007·Molecular Pharmaceutics·Olulanu H AinaKit S Lam
Sep 24, 2010·Bioconjugate Chemistry·Guangchang ZhouStephen J Kron
Mar 8, 2011·ACS Nano·Chuda ChittasuphoCory Berkland